{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper links A30P mutation to early-onset familial Parkinson's disease and describes its defective membrane-binding activity as a pathogenic mechanism.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism as impaired membrane-binding activity of a-Syn, which is implicated in PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses vesicle ultracentrifugation, circular dichroism spectroscopy, and low-angle X-ray diffraction to assess membrane-binding activity.",
          "judgment": "Yes",
          "reasoning": "These assays are standard for evaluating protein-lipid interactions, directly modeling the disease mechanism of membrane-binding defects.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study compares A30P with wild-type a-Syn and A53T mutant, and experiments are performed in triplicate.",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type) and abnormal (A30P) controls are included, with multiple replicates documented.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The A53T mutant is used as a control, showing normal membrane-binding activity compared to A30P.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variant (A30P) and benign variant (A53T) are used as controls, validating the assay's relevance.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "The study reports statistically significant differences in membrane-binding affinity between A30P and wild-type a-Syn.",
          "judgment": "Yes",
          "reasoning": "Statistical tests and confidence intervals are explicitly mentioned, supporting OddsPath calculation.",
          "next_step_or_outcome": "Proceed to Step 4c"
        },
        {
          "step_name": "Step 4c: Correlate OddsPath",
          "extracted_paper_info": "A30P shows defective membrane-binding activity, while A53T maintains normal function; the double mutant mirrors A30P's phenotype.",
          "judgment": "PS3_very_strong",
          "reasoning": "The clear functional defect in A30P (and double mutant) meets ACMG thresholds for very strong pathogenic evidence (OddsPath > 18.7)."
        }
      ],
      "strength": "PS3_very_strong",
      "overall_conclusion": "A30P mutation disrupts a-Syn membrane-binding activity, a critical pathogenic mechanism in Parkinson's disease, supporting strong pathogenic evidence."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper links A53T mutation to normal membrane-binding activity, contrasting with A30P's defective function.",
          "judgment": "Yes",
          "reasoning": "The study defines the disease mechanism as impaired membrane-binding, with A53T as a control showing normal function."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses vesicle ultracentrifugation, circular dichroism spectroscopy, and low-angle X-ray diffraction to assess membrane-binding activity.",
          "judgment": "Yes",
          "reasoning": "These assays are standard for evaluating protein-lipid interactions, directly modeling the disease mechanism of membrane-binding defects.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study compares A53T with wild-type a-Syn and A30P mutant, and experiments are performed in triplicate.",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type) and abnormal (A30P) controls are included, with multiple replicates documented.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The A53T mutant is used as a control, showing normal membrane-binding activity compared to A30P.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variant (A30P) and benign variant (A53T) are used as controls, validating the assay's relevance.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "The study reports statistically significant differences in membrane-binding affinity between A53T and A30P.",
          "judgment": "Yes",
          "reasoning": "Statistical tests and confidence intervals are explicitly mentioned, supporting OddsPath calculation.",
          "next_step_or_outcome": "Proceed to Step 4c"
        },
        {
          "step_name": "Step 4c: Correlate OddsPath",
          "extracted_paper_info": "A53T maintains normal membrane-binding activity, contrasting with A30P's defective function.",
          "judgment": "BS3_very_strong",
          "reasoning": "The preserved normal function of A53T meets ACMG thresholds for very strong benign evidence (OddsPath < 1/18.7)."
        }
      ],
      "strength": "BS3_very_strong",
      "overall_conclusion": "A53T mutation preserves normal membrane-binding activity of a-Syn, consistent with benign functional evidence in Parkinson's disease pathogenesis."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper links A30P mutation to early-onset familial Parkinson's disease and describes its defective membrane-binding activity as a pathogenic mechanism.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism as impaired membrane-binding activity of a-Syn, which is implicated in PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses vesicle ultracentrifugation, circular dichroism spectroscopy, and low-angle X-ray diffraction to assess membrane-binding activity.",
          "judgment": "Yes",
          "reasoning": "These assays are standard for evaluating protein-lipid interactions, directly modeling the disease mechanism of membrane-binding defects.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study compares A30P with wild-type a-Syn and A53T mutant, and experiments are performed in triplicate.",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type) and abnormal (A30P) controls are included, with multiple replicates documented.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The A53T mutant is used as a control, showing normal membrane-binding activity compared to A30P.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variant (A30P) and benign variant (A53T) are used as controls, validating the assay's relevance.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "The study reports statistically significant differences in membrane-binding affinity between A30P and wild-type a-Syn.",
          "judgment": "Yes",
          "reasoning": "Statistical tests and confidence intervals are explicitly mentioned, supporting OddsPath calculation.",
          "next_step_or_outcome": "Proceed to Step 4c"
        },
        {
          "step_name": "Step 4c: Correlate OddsPath",
          "extracted_paper_info": "A30P shows defective membrane-binding activity, while A53T maintains normal function; the double mutant mirrors A30P's phenotype.",
          "judgment": "PS3_very_strong",
          "reasoning": "The clear functional defect in A30P (and double mutant) meets ACMG thresholds for very strong pathogenic evidence (OddsPath > 18.7)."
        }
      ],
      "strength": "PS3_very_strong",
      "overall_conclusion": "A30P mutation disrupts a-Syn membrane-binding activity, a critical pathogenic mechanism in Parkinson's disease, supporting strong pathogenic evidence."
    }
  ]
}